Table 3

EAIRs (95% CI) of IBD by year for patients taking any dose of secukinumab

PsOPsAAS
CDUCIBDUCDUCIBDUCDUCIBDU
Year 1
N=5181		0.12 (0.04 to 0.28)0.17 (0.07 to 0.34)0.00 (0.00 to 0.09)Year 1
N=1380		0.08
(0.00 to 0.43)		0.08
(0.00 to 0.43)		0.08
(0.00 to 0.43)		Year 1
N=794		0.7 (0.2 to 1.6)0.4 (0.1 to 1.2)0.1 (0.0 to
0.7)
Year 2
N=3268		0.00 (0.00 to 0.14)0.20 (0.06 to 0.46)0.00 (0.00 to 0.14)Year 2
N=1183		0.00 (0.00 to 0.34)0.09
(0.00 to 0.52)		0.00 (0.00 to 0.34)Year 2
N=700		0.5 (0.1 to 1.3)0.0 (0.0 to 0.6)0.0 (0.0 to 0.6)
Year 3
N=2246		0.00 (0.00 to 0.20)0.05 (0.00 to 0.30)0.00 (0.00 to 0.20)Year 3
N=948		0.3 (0.0 to 1.0)0.1 (0.0 to 0.8)0.1 (0.0 to 0.8)Year 3
N=557		0.2 (0.0 to 1.3)0.2 (0.0 to 1.3)0.0 (0.0 to 0.9)
Year 4
N=1627		0.00 (0.00 to 0.25)0.07 (0.00 to 0.38)0.07 (0.00 to 0.38)Year 4
N=587		0.0 (0.0 to 0.9)0.0 (0.0 to 0.9)0.0 (0.0 to 0.9)Year 4
N=332		0.0 (0.0 to 3.1)0.0 (0.0 to 3.1)0.0 (0.0 to 3.1)
Year 5
N=1210		0.00 (0.00 to 1.22)0.00 (0.00 to 1.22)0.00 (0.00 to 1.22)Year 5
N=290		0.0 (0.0 to 3.1)0.0 (0.0 to 3.1)0.0 (0.0 to 3.1)NA

  • Year 1: Week 0–52; Year 2: Week 52–104; Year 3: Week 104–156; Year 4: Week 156–208; Year 5: Week 208–260.

  • Data are displayed to two decimals where N>1000; if N<1000, then data are displayed to one decimal.

  • AS, ankylosing spondylitis; CD, Crohn’s disease; EAIR, exposure adjusted incidence rate; IBD, inflammatory bowel disease; IBDU, IBD-unclassified; NA, not available; PsA, psoriatic arthritis; PsO, psoriasis; UC, ulcerative colitis.